Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).
EURneffy is the first needle-free adrenaline treatment option in the EU, offering a more convenient and accessible alternative for adults and children with severe allergies.
It represents the first novel adrenaline delivery method in more than three decades, according to Richard Lowenthal, co-founder, president and CEO of ARS Pharma.
ARS Pharma anticipates that EURneffy will be available to patients in certain European Union member states in the fourth quarter of 2024.
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Blacksmith Medicines granted European patent for LpxC-targeting antibacterial compounds
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS